200 related articles for article (PubMed ID: 33565130)
21. The impact of antibiotics on efficacy of immune checkpoint inhibitors in malignancies: A study based on 44 cohorts.
Wu Q; Liu J; Wu S; Xie X
Int Immunopharmacol; 2021 Mar; 92():107303. PubMed ID: 33465728
[TBL] [Abstract][Full Text] [Related]
22. Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study.
Deschênes-Simard X; Richard C; Galland L; Blais F; Desilets A; Malo J; Cvetkovic L; Belkaid W; Elkrief A; Gagné A; Hamel MA; Orain M; Joubert P; Ghiringhelli F; Routy B; Blais N
Thromb Res; 2021 Sep; 205():29-39. PubMed ID: 34246011
[TBL] [Abstract][Full Text] [Related]
23. Incidence, risk factors and prognosis of acute kidney injury in patients treated with immune checkpoint inhibitors: a retrospective study.
Ji MS; Wu R; Feng Z; Wang YD; Wang Y; Zhang L; Sun XF; Chen XM; He KL; Cai GY
Sci Rep; 2022 Nov; 12(1):18752. PubMed ID: 36335144
[TBL] [Abstract][Full Text] [Related]
24. Predictors of active cancer thromboembolic outcomes. RIETE experience of the Khorana score in cancer-associated thrombosis.
Tafur AJ; Caprini JA; Cote L; Trujillo-Santos J; Del Toro J; Garcia-Bragado F; Tolosa C; Barillari G; Visona A; Monreal M;
Thromb Haemost; 2017 Jun; 117(6):1192-1198. PubMed ID: 28276571
[TBL] [Abstract][Full Text] [Related]
25. Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE.
Robertson L; Yeoh SE; Stansby G; Agarwal R
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD010837. PubMed ID: 28832905
[TBL] [Abstract][Full Text] [Related]
26. Risk Factors for Relapse after Intentional Discontinuation of Immune Checkpoint Inhibitors in Melanoma Patients.
Persa OD; Schatton K; Rübben A; Berking C; Erdmann M; Schlaak M; Mauch C; Steeb T
J Immunother; 2021 Jul-Aug 01; 44(6):239-241. PubMed ID: 34028389
[TBL] [Abstract][Full Text] [Related]
27. Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
Khorana AA; Vadhan-Raj S; Kuderer NM; Wun T; Liebman H; Soff G; Belani C; O'Reilly EM; McBane R; Eikelboom J; Damaraju CV; Beyers K; Dietrich F; Kakkar AK; Riess H; Peixoto RD; Lyman GH
Thromb Haemost; 2017 Nov; 117(11):2135-2145. PubMed ID: 28933799
[TBL] [Abstract][Full Text] [Related]
28. Does prior exposure to immune checkpoint inhibitors treatment affect incidence and mortality of COVID-19 among the cancer patients: The systematic review and meta-analysis.
Liu Y; Liu S; Qin Y; Zhao L; Li Y; Zhou C; Chen W
Int Immunopharmacol; 2021 Dec; 101(Pt A):108242. PubMed ID: 34688136
[TBL] [Abstract][Full Text] [Related]
29. The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors.
Perrone F; Minari R; Bersanelli M; Bordi P; Tiseo M; Favari E; Sabato R; Buti S
J Immunother; 2020; 43(6):196-203. PubMed ID: 32404654
[TBL] [Abstract][Full Text] [Related]
30. The Anticancer Efficacy of Immune Checkpoint Inhibitors According to Patients' Age: A Systematic Review and Meta-Analysis.
Ciccarese C; Iacovelli R; Bria E; Palazzo A; Maiorano BA; Mosillo C; Carbone C; Piro G; Tortora G
J Immunother; 2020 Apr; 43(3):95-103. PubMed ID: 32080018
[TBL] [Abstract][Full Text] [Related]
31. Venous thromboembolism in cancer patients.
Deng A; Galanis T; Graham MG
Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
[TBL] [Abstract][Full Text] [Related]
32. Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK).
Kuderer NM; Poniewierski MS; Culakova E; Lyman GH; Khorana AA; Pabinger I; Agnelli G; Liebman HA; Vicaut E; Meyer G; Shepherd FA
Oncologist; 2018 Feb; 23(2):247-255. PubMed ID: 28951500
[TBL] [Abstract][Full Text] [Related]
33. Immune checkpoint inhibitors for cancer and venous thromboembolic events.
Gong J; Drobni ZD; Alvi RM; Murphy SP; Sullivan RJ; Hartmann SE; Gilman HK; Lee H; Zubiri L; Raghu VK; Karp-Leaf RS; Zafar A; Zlotoff DA; Frigault MJ; Reynolds KL; Neilan TG
Eur J Cancer; 2021 Oct; 158():99-110. PubMed ID: 34662835
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer.
Kobayashi Y; Lim SO; Yamaguchi H
Semin Cancer Biol; 2020 Oct; 65():51-64. PubMed ID: 31874279
[TBL] [Abstract][Full Text] [Related]
35. The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials.
Fujiwara Y; Horita N; Namkoong H; Galsky MD
Eur J Cancer; 2021 Jun; 150():168-178. PubMed ID: 33906099
[TBL] [Abstract][Full Text] [Related]
36. Liver dysfunction is associated with poor prognosis in patients after immune checkpoint inhibitor therapy.
Yokohama K; Asai A; Matsui M; Okamoto N; Yasuoka H; Nishikawa T; Ohama H; Tsuchimoto Y; Inoue Y; Fukunishi S; Uchiyama K; Higuchi K
Sci Rep; 2020 Sep; 10(1):14470. PubMed ID: 32879383
[TBL] [Abstract][Full Text] [Related]
37. Frequency, clinical pattern and outcome of thrombosis in cancer patients in Saudi Arabia.
Aleem A; Al Diab AR; Alsaleh K; Algahtani F; Alsaeed E; Iqbal Z; El-Sherkawy MS
Asian Pac J Cancer Prev; 2012; 13(4):1311-5. PubMed ID: 22799324
[TBL] [Abstract][Full Text] [Related]
38. Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis.
Filippini DM; Gatti M; Di Martino V; Cavalieri S; Fusaroli M; Ardizzoni A; Raschi E; Licitra L
Int J Cancer; 2021 Aug; 149(3):675-683. PubMed ID: 33844854
[TBL] [Abstract][Full Text] [Related]
39. Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab.
Hopkins AM; Kichenadasse G; Garrett-Mayer E; Karapetis CS; Rowland A; Sorich MJ
Clin Cancer Res; 2020 Jul; 26(13):3280-3286. PubMed ID: 32086341
[TBL] [Abstract][Full Text] [Related]
40. Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review.
Spagnolo F; Boutros A; Croce E; Cecchi F; Arecco L; Tanda E; Pronzato P; Lambertini M
Eur J Clin Invest; 2021 Jul; 51(7):e13604. PubMed ID: 34021591
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
